ProCE Banner Activity

CHAARTED: QoL Analysis of Docetaxel + ADT in Metastatic Hormone-Sensitive Prostate Cancer

Slideset Download
Conference Coverage
Patient-reported outcomes from CHAARTED indicate that adding docetaxel to ADT increased physical symptoms during first 3 months of treatment but was associated with significantly improved QoL at 12 mos in patients with mHSPC.

Released: June 07, 2016

Expiration: June 06, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals